Two studies published in this issue of the Journal of the American Heart Association (JAHA) give us some idea of how medical therapy will more often be considered a core component of the management of aortic abdominal aneurysms.
First, a meta-analysis by Al-Omran and colleagues 2 12 In contrast to doxycycline, fluoroquinolones may potentiate aneurysm growth and rupture. Preclinical work from LeMaire and colleagues, demonstrating that increased matrix metalloproteinase activity is one of several effects of ciprofloxacin, 13 provides an important piece of evidence that makes the association of ciprofloxacin and aneurysm rupture 14 more compelling.
Population-level and preclinical studies suggest metformin may also slow aneurysm growth. 15, 16 Randomized trials of metformin therapy have been performed on nondiabetic populations (including, for example, nondiabetic subjects with coronary artery disease), 17 so further studies of metformin as a potential medical therapy for abdominal aneurysms may be forthcoming. While searching for medical therapies, we should not forget the impact of lifestyle on aneurysms. The aneurysm mortality incidence rate in the United States closely mirrors per capita cigarette consumption rates, and it is encouraging that rates of both are decreasing sharply. 18 Clinicians must discuss tobacco use at each clinic visit, emphasize the health benefits of smoking cessation, and provide support to achieve complete abstinence (including free resources from smokefree.gov and 800-QUIT-NOW). We now know, from the work of Dalman and colleagues, that although exercise therapy does
The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. *Peripheral artery disease, "atherosclerotic disease of the lower extremity arteries," 3 is common among patients with abdominal aortic aneurysms. 4 The pathogenesis of these 2 processes appears to share many features. 5 By themselves, however, abdominal aortic aneurysms do not constitute peripheral artery disease, so the most recent guideline on cholesterol management 6 does not seem to endorse statin therapy in patients who have abdominal aneurysms but do not have peripheral artery disease of presumed atherosclerotic origin or other listed indications for statin therapy. not halt growth, it is perfectly safe for people with aneurysms to exercise regularly. 19 In summary, experimental studies evaluating medical therapies for abdominal aortic aneurysms suggest benefit from statins, doxycycline, and possibly metformin. Fluoroquinolones and tobacco seem harmful. Exercise does not adversely affect abdominal aneurysms and should be encouraged for the countless other benefits provided.
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